Kush M. Parmar, M.D., Ph.D. is a Managing Partner at 5AM Ventures, a leading investment firm focused on funding and building next-generation life science companies. He currently serves on the Boards of Ensoma, Entrada (TRDA), GlycoEra, Precede Bioscience, and ProLynx, and has guided companies through IPOs, acquisitions, and major partnerships; including Arvinas (ARVN), Audentes (acquired by Astellas), Akouos (acquired by Eli Lilly), Homology (FIXX), Rallybio (RLYB), and Vor Biopharma (VOR). Dr. Parmar is also active in India’s biotech ecosystem as a Board Member of Syngene International (SYNGENE) and as a co-founder of Immuneel Therapeutics.

Parmar serves on the Board of Fellows of Harvard Medical School and is a Fellow of the Kauffman Fellows Society. Prior to 5AM, he trained as an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. At Princeton, he studied developmental genetics with 1995 Nobel Prize laureate Eric Wieschaus. Dr. Parmar earned his A.B. in Molecular Biology and Medieval Studies from Princeton, a Ph.D. in Experimental Pathology from Harvard, and an M.D. from Harvard Medical School.